What's in CuraSen Therapeutics, Inc.'s pipeline?

CuraSen Therapeutics, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with CuraSen Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Astellas Pharma Inc, Bayer, Eagle Pharmaceuticals, Inc., Eli Lilly and Company, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/curasen-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

CuraSen Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

CuraSen Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma Inc · 1 shared drug class
Bayer · 1 shared drug class
Eagle Pharmaceuticals, Inc. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CuraSen Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). CuraSen Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/curasen-therapeutics-inc. Accessed 2026-05-16.